Clearmind Medicine (CMND) said Thursday that the Macau International Intellectual Property Office has granted a patent for its binge behavior treatment.
The patent is directed to be used a a primary amine aminoindan compound for binge behavior regulation, including such compounds beyond its psychedelic molecule, 5-methoxy-2-aminoindan.
Shares of Clearmind Medicine were up over 7% in premarket activity Thursday.
Price: 1.48, Change: +0.10, Percent Change: +7.25